Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed David P. Wright to its board of directors.
Agilent Technologies Inc., of Santa Clara, Calif., appointed William Molnar vice president and general manager of the Stratagene division.
Allon Therapeutics Inc., of Vancouver, British Columbia, appointed Annette Kleiser vice president of business development.
Biodel Inc., of Danbury, Conn., named Ralf Rosskamp to its scientific advisory board.
CryoCath Technologies Inc., of Montreal, named Jesse Penn to its board of directors.
Cytochroma Inc., of Markham, Ontario, named Gordon Ngan executive director of corporate development.
Deciphera Pharmaceuticals LLC, of Lawrence, Kan., appointed James A. Bristol to its board of managers.
EBioscience Corp., of San Diego, appointed Todd R. Nelson CEO.
Emisphere Technologies Inc., of Tarrytown, N.Y., named Michael R. Garone chief financial officer and appointed Paul Lubetkin vice president and general counsel.
EPIX Pharmaceuticals, of Lexington, Mass., named Margaret Uprichard senior vice president of regulatory affairs and quality.
EyeGate Pharma, of Waltham, Mass., appointed Paul G. Chaney to its board of directors.
IDM Pharma, of Irvine, Calif., named Jeffrey W. Sherman chief medical officer and senior vice president of research and development.
Immtech Pharmaceuticals Inc., of New York, named David Fleet to its board of directors.
Magellan Biosciences, of Chelmsford, Mass., named Steven E. Diamond chief scientific officer. The company also named Heiner Dreismann, Laurence R. McCarthy and Stuart A. Auerbach to its board of directors.
MIT Holding Inc., of Savannah, Ga., appointed Thomas M. Kollars Jr. chief scientific advisor.
NanoLogix Inc., of Hubbard, Ohio, named Chris R. Novak director of intellectual property.
Nektar Therapeutics, of San Carlos, Calif., appointed Tim Harkness senior vice president and chief financial officer. The company also named Lutz Lingnau to its board of directors.
Novalar Pharmaceuticals Inc., of San Diego, named Steven J. Semmelmayer to its board of directors.
Nucryst Pharmaceuticals Corp., of Wakefield, Mass., appointed Thomas E. Gardner chairman, president and CEO.
Prestwick Pharmaceuticals Inc., of Washington, named Robert S. Radie executive vice president and chief business officer. The company also appointed Martin Stogniew executive vice president and chief technology officer.
ProtAffin AG, of Graz, Austria, named Timothy Wells and Marco Sardinia to its scientific advisory board.
ResMed Inc., of San Diego, appointed Kieran T. Gallahue CEO and named him to its board of directors.
Ventaira Pharmaceuticals Inc., of Columbus, Ohio, appointed Lex Adjei vice president of research and development.
VisEn Medical Inc., of Woburn, Mass., appointed Tarif Awad director of external scientific collaborations.